Flex Pharma (FLKS) Tops Q3 EPS by 7c

Flex Pharma (NASDAQ: FLKS) reported Q3 EPS of ($0.65), $0.07 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $586 thousand versus the consensus estimate of $110 thousand.

For earnings history and earnings-related data on Flex Pharma (FLKS) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Bernstein SocGen Group Upgrades Whitbread PLC. (WTB:LN) (WTBCF) to Market Perform
• Barclays Upgrades Schott Pharma AG (1SXP:GR) to Overweight